New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
13:21 EDTMNOVMedicNova price target lowered to $6 from $10.50 at Ladenburg
Ladenburg reduced its target on MedicNova after the company indicated that the FDA would require the company to show through a Phase III trial that its asthma treatment reduces hospitalizations. However, the firm continues to be upbeat on the stock and maintains a Buy rating.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
19:01 EDTMNOVMediciNova announces completion of enrollment in MN-166 clinical trial
MediciNova announced that the clinical trial of MN-166 in alcohol dependence has completed enrollment of 24 subjects. Yuichi Iwaki, MD, PhD, president and CEO of MediciNova, commented, "We are pleased that enrollment is now completed in our first study of MN-166 in alcohol dependence. We look forward to the final results of the study."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use